Emergent Biosolutions Inc
NYSE: EBS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Updated 2026-09-18
Emergent Biosolutions Inc (EBS) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for EBS.
Valued
Valuation reasonably reflects current fundamentals. Limited margin of safety at these levels.
EBS historical valuation range
Where current P/E sits in EBS's own 5Y range.
EBS intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
EBS valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
P/S Ratio — History
Current: 0.41x
Is EBS overvalued in 2026?
Emergent Biosolutions Inc (EBS) currently trades at $6.78 per share with a market capitalization of $319,433,000.00. Based on our multi-factor framework, the stock trades at a fair valuation with a Smart Value Score of 64/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
EBS currently has no meaningful P/E ratio, which typically signals that the company is unprofitable, near breakeven, or emerging from a loss-making period. With a P/S ratio of 0.4x, the market is valuing the company primarily on its revenue rather than its earnings.
Looking at its own history, EBS is currently trading cheaper than 100% of the last 5Y on P/E. This places it in the 0th percentile of its historical range, a level that has historically coincided with attractive entry points.
Our discounted cash flow model estimates EBS's intrinsic value at $33.92 per share, against the current market price of $6.78. This implies a margin of safety of +67.48%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: EBS trades at a fair valuation on our framework, with a Smart Value Score of 64/100. The valuation is defensible but offers no obvious bargain. Patience or a better entry price may reward disciplined buyers.
Frequently asked questions
Is EBS overvalued?
EBS scores 64/100 on our Smart Value Score (Grade C+), a mixed overall profile. The DCF also shows a positive margin of safety, so price and fundamentals line up reasonably well.
What is EBS's fair value?
Our DCF model estimates EBS's intrinsic value at $33.92 per share, versus the current price of $6.78, a margin of safety of +67.48%. Fair value is the present value of the cash flows we project the business to produce, so a price below it means the market is pricing the stock below that conservative estimate.
What P/E ratio does EBS trade at?
EBS does not have a meaningful P/E right now, usually a sign of unprofitability or an earnings transition. For unprofitable growth names, price-to-sales is the more useful gauge.
Is EBS a buy based on valuation?
Our Smart Value rating for EBS is Hold, from a Smart Value Score of 64/100 that blends growth, quality, and valuation. The profile is balanced and best suited to investors who already have a thesis. This is research to inform your decision, not personalized financial advice.
How does EBS's valuation compare to its history?
On P/E, EBS sits in the 0th percentile of its own 5Y range, historically cheap relative to where it has traded. A low percentile means today's multiple is near the bottom of its historical band.
What is EBS's Smart Value Score?
EBS's Smart Value Score is 64/100. It is a proprietary WallStSmart metric blending growth quality, financial health, and valuation into a single 0-100 read, and scores above 75 are rare, signaling strong multi-factor alignment.